A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis

Summary

The purpose of study BMX-05-001 is to evaluate the safety, tolerability, efficacy, and pharmacodynamics of BX005-A compared to vehicle administered topically in adult subjects with moderate to severe atopic dermatitis (AD).

Timeline

Start

2022-05

Primary completion

2023-06

Completion

2023-06

Outcome

Outcome not reported

Stopped (Enrollment): “Study did not start enrollment due to business reasons”

Drugs

Indications